البلد: ماليزيا
اللغة: الإنجليزية
المصدر: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
DOXORUBICIN HYDROCHLORIDE
Dr. Reddy`s Laboratories Malaysia Sdn. Bhd.
DOXORUBICIN HYDROCHLORIDE
20mg/10 ml; 50mg/25 ml
Natco Pharma Ltd.
Not Applicable اقرأ الوثيقة كاملة
DOXLOX DOXORUBICIN HCL LIPOSOME INJECTION CONCENTRATE FOR SOLUTION FOR INFUSION 2 MG/ML (PEGYLATED LIPOSOMAL FORMULATION) COMPOSITION: Each ml of Doxlox contains 2 mg doxorubicin hydrochloride in a pegylated liposomal formulation. PRODUCT DESCRIPTION: Doxorubicin hydrochloride liposome injection is a translucent, red liposomal dispersion. DESCRIPTION AFTER DILUTION: A translucent red liposomal dispersion. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS Doxorubicin is indicated: - As monotherapy for patients with metastatic breast cancer - For treatment of advanced ovarian cancer in women who have failed a rst-line platinum-based chemotherapy regimen. - In combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. - For treatment of AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (< 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. Doxorubicin may be used as rst-line systemic chemotherapy, or as second line chemotherapy in AIDS-KS patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline). POSOLOGY AND METHOD OF ADMINISTRATION Doxorubicin should only be administered under the supervision of a qualied oncologist specialised in the administration of cytotoxic agents. Doxorubicin exhibits unique pharmacokinetic properties and must not be used interchangeably with other formulations of doxorubicin hydrochloride. Posology _Breast cancer/Ovarian cancer_ 2 Doxorubicin is administered intravenously at a dose of 50 mg/m once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment. _Multiple myeloma_ Doxorubicin is administered at 30 mg/m² on day 4 of the bortezomib 3 week regimen as a 1 hour اقرأ الوثيقة كاملة